TrialBlood cancer journal2025

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Gurdeep Parmar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.